NEWS & EVENTS

A new treatment for osteoarthritis

NEWS - 16TH MARCH 2020

The Regenerative Clinic launches nSTRIDE autologous protein injections for the relief of degenerative or trauma related musculoskeletal injuries

The Regenerative Clinic has added a new treatment called nSTRIDE Autologous Protein Injections to its portfolio of rejuvenating orthobiologic therapies. The nSTRIDE protein injection, which uses protein taken from the patient’s own body to treat osteoarthritis and other degenerative or trauma related musculoskeletal injuries, has been shown to provide pain relief in 70% of patients, with results recorded regularly throughout and up to three years following treatment.

It is a day case procedure in which blood is drawn from the patient’s arm, and then processed using a centrifuge that separates the platelet-rich plasma (PRP). The centrifuge further processes this into a concentrated liquid protein, which is then injected back into the patient’s knee.

Orthobiologic medicine
nSTRIDE adds to The Regenerative Clinic’s portfolio, which offers the latest advances in orthobiologic medicine. Simon Checkley, CEO of The Regenerative Clinic says: “Results to date with nSTRIDE are extremely impressive and we are proud to offer this very exciting treatment. Our mission is to continue to help people who are in the pervasive pain of osteoarthritis. nSTRIDE is viable, safe and, with treatment times of only an hour, a rapid treatment choice to reduce pain and delay the need for surgery.”

nSTRIDE has been the subject of a number of research papers that demonstrate good outcomes, especially for knee osteoarthritis. According to a recent study, a 70% improvement in osteoarthritic knee pain was shown two years following a single injection. The paper’s authors wrote: “A single intraarticular nSTRIDE APS injection is safe (similar to a saline injection) and continues to provide pain improvement at one year.” This measurement is based on the WOMAC scoring system, which is a much more stringent measurement than standard VAS scoring, so 70% is very positive.

nSTRIDE is available at The Regenerative Clinic’s flagship clinic at the Queen Anne Hospital in the Harley Street Medical Area. Patients will be assessed by an expert consultant in their specific pathology to ascertain suitability for treatment.